{"id":"NCT00336505","sponsor":"Advanced Life Sciences, Inc.","briefTitle":"Study Comparing the Safety and Efficacy of Cethromycin to Clarithromycin for the Treatment of Community-Acquired Pneumonia (CAP)","officialTitle":"A Double-Blinded, Randomized, Parallel Group, Multi-Center, Multi-National Comparative Study of the Safety and Efficacy of Cethromycin 300 mg QD to Clarithromycin (BIAXIN® Filmtab®) 250 mg BID for the Treatment of Community-Acquired Pneumonia in Adults","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-12","primaryCompletion":"2007-10","completion":"2007-10","firstPosted":"2006-06-13","resultsPosted":"2010-02-26","lastUpdate":"2010-02-26"},"enrollment":584,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Pneumonia"],"interventions":[{"type":"DRUG","name":"Cethromycin","otherNames":["Restanza","ABT-773"]},{"type":"DRUG","name":"Clarithromycin","otherNames":["Biaxin","Klacid","Klaracid"]}],"arms":[{"label":"Clarithromycin","type":"ACTIVE_COMPARATOR"},{"label":"Cethromycin","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to compare the efficacy of cethromycin to clarithromycin for the treatment of mild to moderate community-acquired pneumonia (CAP).","primaryOutcome":{"measure":"Clinical Cures in the Intent to Treat Population","timeFrame":"Test of Cure Visit, defined as 14-22 days after the first dose of study drug.","effectByArm":[{"arm":"Cethromycin","deltaMin":217,"sd":null},{"arm":"Clarithromycin","deltaMin":206,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.5667"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":20},"locations":{"siteCount":3,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":13,"n":288},"commonTop":["Dysgeusia","Diarrhea","Nausea","Headache","Urinary tract infection"]}}